PROQR THRAPEUTICS N V's ticker is PRQR and the CUSIP is N71542109. A total of 69 filers reported holding PROQR THRAPEUTICS N V in Q3 2021. The put-call ratio across all filers is 1.13 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $5 | -28.6% | 4,600 | 0.0% | 0.00% | 0.0% |
Q2 2023 | $7 | -22.2% | 4,600 | 0.0% | 0.00% | 0.0% |
Q1 2023 | $9 | -43.8% | 4,600 | 0.0% | 0.00% | 0.0% |
Q4 2022 | $16 | -99.6% | 4,600 | -20.7% | 0.00% | – |
Q3 2022 | $4,000 | -20.0% | 5,800 | -37.5% | 0.00% | – |
Q2 2022 | $5,000 | -82.8% | 9,276 | -70.2% | 0.00% | -100.0% |
Q1 2022 | $29,000 | -61.8% | 31,176 | +171.9% | 0.00% | -33.3% |
Q4 2021 | $76,000 | -29.6% | 11,466 | -38.7% | 0.00% | -40.0% |
Q3 2021 | $108,000 | +140.0% | 18,700 | +156.2% | 0.01% | +150.0% |
Q2 2021 | $45,000 | +25.0% | 7,300 | -57.3% | 0.00% | +100.0% |
Q1 2021 | $36,000 | +800.0% | 17,100 | +402.9% | 0.00% | – |
Q4 2020 | $4,000 | +33.3% | 3,400 | +240.0% | 0.00% | – |
Q3 2020 | $3,000 | -94.9% | 1,000 | -93.1% | 0.00% | -100.0% |
Q2 2020 | $59,000 | +90.3% | 14,500 | +57.6% | 0.00% | +100.0% |
Q1 2020 | $31,000 | +1450.0% | 9,200 | +411.1% | 0.00% | – |
Q4 2019 | $2,000 | – | 1,800 | +800.0% | 0.00% | – |
Q4 2018 | $0 | – | 200 | 0.0% | 0.00% | – |
Q3 2018 | $0 | – | 200 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Aquilo Capital Management, LLC | 2,401,570 | $14,602,000 | 2.94% |
DAFNA Capital Management LLC | 1,237,400 | $7,523,000 | 2.17% |
RTW INVESTMENTS, LP | 4,902,785 | $29,809,000 | 0.84% |
Kerrisdale Advisers, LLC | 453,182 | $2,755,000 | 0.31% |
COWEN AND COMPANY, LLC | 300,042 | $1,824,000 | 0.30% |
Artal Group S.A. | 1,259,177 | $7,656,000 | 0.21% |
ADAGE CAPITAL PARTNERS GP, L.L.C. | 4,550,062 | $27,664,000 | 0.07% |
ALTRINSIC GLOBAL ADVISORS LLC | 221,360 | $1,346,000 | 0.06% |
FRANKLIN STREET ADVISORS INC /NC | 60,000 | $365,000 | 0.04% |
JENNISON ASSOCIATES LLC | 2,625,514 | $15,963,000 | 0.01% |